Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?
Open Access
- 1 January 2020
- journal article
- letter
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 34
Abstract
Bronchial asthma is a heterogeneous disease whose definition and treatment are based on evidence of variable airway obstruction and airway inflammation. Despite the enormous increase in the amount of information on the pathogenesis of this disease, diagnosis is still an unresolved problem, as we still lack sensitive and specific biomarkers. On the other hand, at the turn of the 20th and 21st century, there was a rapid development of therapeutic modalities based on the principle of biological therapy. The first authorized drug matching these characteristics was omalizumab – a monoclonal antibody directed against immunoglobulin E (IgE). It has been used for the treatment of severe forms of bronchial asthma for more than 15 years, which is a sufficient time to acquire ways of its effective use and to assess whether the treatment with omalizumab has met our expectations. However, we continue to discover new and surprising facts about the effects of omalizumab treatment which leads to widening of therapeutic indications. In this work, a basic overview of the very complex role of the IgE molecule in the organism (with a special emphasis on allergic asthma) is discussed, and the most important practical and clinical consequences resulting from its modulation by targeted therapy with omalizumab are summarized.Keywords
Funding Information
- Charles Darwin University (PROGRESS Q40)
This publication has 94 references indexed in Scilit:
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammationBMC Pulmonary Medicine, 2013
- The Role of IgE-Receptors in IgE-Dependent Airway Smooth Muscle Cell RemodellingPLOS ONE, 2013
- Physical activity in adults with controlled and uncontrolled asthma as compared to healthy adults: a cross‐sectional studyClinical and Translational Allergy, 2013
- Functional exercise capacity and health-related quality of life in people with asbestos related pleural disease: an observational studyBMC Pulmonary Medicine, 2013
- Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cellsClinical and Translational Allergy, 2013
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgEBritish Journal of Clinical Pharmacology, 2011
- Signaling pathways critical for allergic airway inflammationCurrent Opinion in Allergy and Clinical Immunology, 2010
- IgE, mast cells, basophils, and eosinophilsJournal of Allergy and Clinical Immunology, 2010